Ubiquitous Aberrant RASSF1A Promoter Methylation in Childhood Neoplasia

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 994-1002

  Wong, Ivy H N ^a   Chan, Jacqueline ^a   Wong, Joyce ^a   Tam, Paul K H ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLIN D1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADRENAL CORTEX CARCINOMA; ALLELE; APOPTOSIS; ARTICLE; BLASTOMA; BLOOD CELL; BURKITT LYMPHOMA; CANCER SURVIVAL; CELL CYCLE; CELL DEATH; CHILD; CHILDHOOD CANCER; CHROMOSOME ABERRATION; CLINICAL ARTICLE; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; LIVER CELL CARCINOMA; MALE; METASTASIS; NEOPLASM; NEPHROBLASTOMA; NEUROBLASTOMA; NEWBORN; PANCREAS TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LYMPHOMA; THYROID CARCINOMA; TRANSCRIPTION REGULATION; TUMOR VOLUME;

ADOLESCENT; ALLELES; CELL LINE; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CYCLIN D1; DNA METHYLATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASM METASTASIS; NEOPLASMS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TUMOR SUPPRESSOR PROTEINS;

EID: 1042301960     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0378-3     Document Type: Article

References (52)

1. Ganjavi, H., and Malkin, D. Genetics of childhood cancer. Clin. Orthop., 401: 75-87, 2002.
2. Davidoff, A. M., and Hill, D. A. Molecular genetic aspects of solid tumors in childhood. Semin. Pediatr. Surg., 10: 106-118, 2001.
3. Loeb, L. A. A mutator phenotype in cancer. Cancer Res., 61: 3230-3239, 2001.
4. Esteller, M., Corn, P. G., Baylin, S. B., and Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res., 61: 3225-3229, 2001.
5. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
6. Vojtek, A. B., and Der, C. J. Increasing complexity of the Ras signaling pathway. J. Biol. Chem., 273: 19925-19928, 1998.
7. Mulcahy, L. S., Smith, M. R., and Stacey, D. W. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature (Lond.), 313: 241-243, 1985.
8. Lowy, D. R., and Willumsen, B. M. Function and regulation of ras. Annu. Rev. Biochem., 62: 851-891, 1993.
9. Takiguchi, Y., Takahashi, Y., Kuriyama, T., and Miyamoto, T. NIH3T3 transfectant containing human K-ras oncogene shows enhanced metastatic activity after in vivo tumor growth or co-culture with fibroblasts. Clin. Exp. Metastasis, 10: 351-360, 1992.
10. Andrejauskas, E., and Moroni, C. Reversible abrogation of IL-3 dependence by an inducible H-ras oncogene. EMBO J., 8: 2575-2581, 1989.
11. Huber, B. E., and Cordingley, M. G. Expression and phenotypic alterations caused by an inducible transforming ras oncogene introduced into rat liver epithelial cells. Oncogene, 3: 245-256, 1988.
12. Yuspa, S. H., Kilkenny, A. E., Stanley, J., and Lichti, U. Keratinocytes blocked in phorbol ester-responsive early stage of terminal differentiation by sarcoma viruses. Nature (Lond.), 314: 459-462, 1985.
13. Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., and Evan, G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature (Lond.), 385: 544-548, 1997.
14. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88: 593-602, 1997.
15. Chi, S., Kitanaka, C., Noguchi, K., Mochizuki, T., Nagashima, Y., Shirouzu, M., Fujita, H., Yoshida, M., Chen, W., Asai, A., Himeno, M., Yokoyama, S., and Kuchino, Y. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene, 18: 2281-2290, 1999.
16. Mayo, M. W., Wang, C. Y., Cogswell, P. C., Rogers-Graham, K. S., Lowe, S. W., Der, C. J., and Baldwin, A. S., Jr. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (Wash. DC), 278: 1812-1815, 1997.
17. Ejeskar, K., Aburatani, H., Abrahamsson, J., Kogner, P., and Martinsson, T. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br. J. Cancer, 77: 1787-1791, 1998.
18. Astuti, D., Agathanggelou, A., Honorio, S., Dallol, A., Martinsson, T., Kogner, P., Cummins, C., Neumann, H. P., Voutilainen, R., Dahia, P., Eng, C., Maher, E. R., and Latif, F. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene, 20: 7573-7577, 2001.
19. Dammann, R., Li, C., Yoon, J. H., Chin, P. L., Bates, S., and Pfeifer, G. P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet., 25: 315-319, 2000.
20. Dammann, R., Yang, G., and Pfeifer, G. P. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res., 61: 3105-3109, 2001.
21. Kuzmin, I., Gillespie, J. W., Protopopov, A., Geil, L., Dreijerink, K., Yang, Y., Vocke, C. D., Duh, F. M., Zabarovsky, E., Minna, J. D., Rhim, J. S., Emmert-Buck, M. R., Linehan, W. M., and Lerman, M. I. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res., 62: 3498-3502, 2002.
22. Ponting, C. P., and Benjamin, D. R. A novel family of Ras-binding domains. Trends Biochem. Sci., 21: 422-425, 1996.
23. Kim, S. T., Lim, D. S., Canman, C. E., and Kastan, M. B. Substrate specificities and identification of putative substrates of ATM kinase family members. J. Biol. Chem., 274: 37538-37543, 1999.
24. Newton, A. C. Protein kinase C: seeing two domains. Curr. Biol., 5: 973-976, 1995.
25. Knudson, A. G., Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA, 68: 820-823, 1971.
26. Agathanggelou, A., Honorio, S., Macartney, D. P., Martinez, A., Dallol, A., Rader, J., Fullwood, P., Chauhan, A., Walker, R., Shaw, J. A., Hosoe, S., Lerman, M. I., Minna, J. D., Maher, E. R., and Latif, F. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20: 1509-1518, 2001.
27. Burbee, D. G., Forgacs, E., Zochbauer-Muller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Kondo, M., Virmani, A., Bader, S., Sekido, Y., Latif, F., Milchgrub, S., Toyooka, S., Gazdar, A. F., Lerman, M. I., Zabarovsky, E., White, M., and Minna, J. D. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst. (Bethesda), 93: 691-699, 2001.
28. Shivakumar, L., Minna, J., Sakamaki, T., Pestell, R., and White, M. A. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol. Cell. Biol., 22: 4309-4318, 2002.
29. Wong, I. H. N., Ng, M. H. L., Lee, J. C. K., Lo, K. W., Chung, Y. F., and Huang, D. P. Transcriptional silencing of the p16 gene by hypermethylation in human myeloma-derived cell lines. Br. J. Haematol., 103: 168-175, 1998.
30. Wong, I. H. N., Lo, Y. M. D., Zhang, J., Liew, C. T., Ng, M. H. L., Wong, N., Lai, P. B. S., Lau, W. Y., Hjelm, N. M., and Johnson, P. J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res., 59: 71-73, 1999.
31. Wong, I. H. N., Ng, M. H. L., Huang, D. P., and Lee, J. C. K. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all the morphologic subtypes: potential prognostic implications. Blood, 95: 1942-1949, 2000.
32. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
33. Wong, I. H. N., Leung, T., Ho, S., Lau, W. Y., Chan, M., and Johnson, P. J. Semiquantification of circulating hepatocellular carcinoma cells by reverse transcriptase polymerase chain reaction. Br. J. Cancer, 76: 628-633, 1997.
34. Dammann, R., Takahashi, T., and Pfeifer, G. P. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene, 20: 3563-3567, 2001.
35. Yoon, J. H., Dammann, R., and Pfeifer, G. P. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer, 94: 212-217, 2001.
36. Dreijerink, K., Braga, E., Kuzmin, I., Geil, L., Duh, F. M., Angeloni, D., Zbar, B., Lerman, M. I., Stanbridge, E. J., Minna, J. D., Protopopov, A., Li, J., Kashuba, V., Klein, G., and Zabarovsky, E. R. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc. Natl. Acad. Sci. USA, 98: 7504-7509, 2001.
37. Morrissey, C., Martinez, A., Zatyka, M., Agathanggelou, A., Honorio, S., Astuti, D., Morgan, N. V., Moch, H., Richards, F. M., Kishida, T., Yao, M., Schraml, P., Latif, F., and Maher, E. R. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res., 61: 7277-7281, 2001.
38. Byun, D. S., Lee, M. G., Chae, K. S., Ryu, B. G., and Chi, S. G. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res., 61: 7034-7038, 2001.
39. Toyooka, S., Pass, H. I., Shivapurkar, N., Fukuyama, Y., Maruyama, R., Toyooka, K. O., Gilcrease, M., Farinas, A., Minna, J. D., and Gazdar, A. F. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res., 61: 5727-5730, 2001.
40. Harada, K., Toyooka, S., Maitra, A., Maruyama, R., Toyooka, K. O., Timmons, C. F., Tomlinson, G. E., Mastrangelo, D., Hay, R. J., Minna, J. D., and Gazdar, A. F. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene, 21: 4345-4349, 2002.
41. van Engeland, M., Roemen, G. M., Brink, M., Pachen, M. M., Weijenberg, M. P., de Bruine, A. P., Arends, J. W., van den Brandt, P. A., de Goeij, A. F., and Herman, J. G. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene, 21: 3792-3795, 2002.
42. Rodenhuis, S. ras and human tumors. Semin. Cancer Biol., 3: 241-247, 1992.
43. Lee, M. G., Kim, H. Y., Byun, D. S., Lee, S. J., Lee, C. H., Kim, J. I., Chang, S. G., and Chi, S. G. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res., 61: 6688-6692, 2001.
44. Maruyama, R., Toyooka, S., Toyooka, K. O., Harada, K., Virmani, A. K., Zochbauer-Muller, S., Farinas, A. J., Vakar-Lopez, F., Minna, J. D., Sagalowsky, A., Czerniak, B., and Gazdar, A. F. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res., 61: 8659-8663, 2001.
45. Park, B. J., Park, J. I., Byun, D. S., Park, J. H., and Chi, S. G. Mitogenic conversion of transforming growth factor-β1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res., 60: 3031-3038, 2000.
46. Maruyama, R., Toyooka, S., Toyooka, K. O., Virmani, A. K., Zochbauer-Muller, S., Farinas, A. J., Minna, J. D., McConnell, J., Frenkel, E. P., and Gazdar, A. F. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res., 8: 514-519, 2002.
47. Belinsky, S. A., Nikula, K. J., Palmisano, W. A., Michels, R., Saccomanno, G., Gabrielson, E., Baylin, S. B., and Herman, J. G. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA, 95: 11891-11896, 1998.
48. Khokhlatchev, A., Rabizadeh, S., Xavier, R., Nedwidek, M., Chen, T., Zhang, X. F., Seed, B., and Avruch, J. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol., 12: 253-265, 2002.
49. Wong, I. H. N., Lo, Y. M., Yeo, W., Lau, W. Y., and Johnson, P. J. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin. Cancer Res., 6: 2521-3516, 2000.
50. Wong, I. H. N. Methylation profiling of human cancers in blood: molecular monitoring and prognostication. Int. J. Oncol., 19: 1319-1324, 2001.
51. Wong, I. H. N., Lo, Y. M., and Johnson, P. J. Epigenetic tumor markers in plasma and serum: biology and applications to molecular diagnosis and disease monitoring. Ann. N. Y. Acad. Sci., 945: 36-50, 2001.
52. Lovell, M., Lott, S. T., Wong, P., El-Naggar, A., Tucker, S., and Killary, A. M. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. Cancer Res., 59: 2182-2189, 1999.